Group by: Item Type | No Grouping
Number of items: 2.

Article

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Ruiz, I, Perelló, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Máhr, K, Schenker, M, Sohn, J, Lee, KS, Shepherd, CJ, Oelmann, E, Sarker, S-J, Prendergast, A, Marosics, P, Moosa, A, Lawrence, C, Coetzee, C, Mousa, K and Cortés, J (2019) Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5 (11). 1556 - 1556.

Conference or Workshop Item

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Cabrero, IR, Perello, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Mahr, K, Schenker, M, Sohn, JH, Lee, KS, Sarker, S-J, Coetzee, C, Mousa, K and Castan, JC (2018) MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. In: 2017 San Antonio Breast Cancer Symposium, December 5-9 2017, San Antonio, Texas.

This list was generated on Wed Nov 1 00:40:19 2023 UTC.